Actinium Pharmaceuticals has patented a method using radiolabeled anti-CD45 antibodies to deplete hematopoietic stem cells in human subjects for genetically edited cell therapy. The method targets non-cancerous disorders like hemoglobinopathy, immunodeficiency, or viral infections, reducing stem cell populations by specified percentages. GlobalData’s report on Actinium Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Actinium Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Actinium Pharmaceuticals, Antibody drug conjugates(ADC) cancer therapy was a key innovation area identified from patents. Actinium Pharmaceuticals's grant share as of February 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11912780B2) outlines a method for depleting hematopoietic stem cells in human subjects to prepare for genetically edited hematopoietic stem cell therapy. The method involves administering a radiolabeled anti-CD45 antibody, specifically radiolabeled BC8 with 131I or 225Ac, to individuals with non-cancerous disorders such as hemoglobinopathies, congenital immunodeficiencies, or viral infections. The depletion of hematopoietic stem cells aims to reduce their population by varying percentages, ranging from 10% to 99%. The effective amount of the radiolabeled BC8, whether 131I-BC8 or 225Ac-BC8, is crucial and administered as a single dose.

Furthermore, the patent details the treatment of non-cancerous disorders like sickle cell disease (SCD) or severe combined immunodeficiency disease (SCID) through genetically edited hematopoietic stem cell therapy post-depletion of stem cells. The genetically edited therapy can involve specific genes like the common gamma chain (?c) gene or adenosine deaminase (ADA) gene. The radiolabeled BC8, whether 131I-BC8 or 225Ac-BC8, is administered in varying effective amounts based on subject weight, ranging from 0.1 µCi/kg to 5.0 µCi/kg. The patent also includes an article of manufacture comprising the radiolabeled anti-CD45 antibody and instructions for administration to achieve the desired depletion of hematopoietic stem cells, emphasizing the importance of precise dosages for optimal therapeutic outcomes.

To know more about GlobalData’s detailed insights on Actinium Pharmaceuticals, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies